Hawaii SB969 mandates insurance coverage for biomarker testing in Hawaii starting January 1, 2026.

Hawaii SB969 requires insurance policies and contracts to cover biomarker testing for diagnosis, treatment, and management of diseases or conditions, starting January 1, 2026. Biomarker testing includes analysis of tissue, blood, or other biospecimens for gene mutations, gene characteristics, and protein expression. Insurers must provide a process for requesting exceptions to coverage. The bill also mandates that the Hawaii Department of Human Services amend the Medicaid state plan to include these coverage requirements.

Hawaii SB969 mandates insurance coverage for biomarker testing in Hawaii starting January 1, 2026.

Hawaii SB969 requires insurance policies and contracts to cover biomarker testing for diagnosis, treatment, and management of diseases or conditions, starting January 1, 2026. Biomarker testing includes analysis of tissue, blood, or other biospecimens for gene mutations, gene characteristics, and protein expression. Insurers must provide a process for requesting exceptions to coverage. The bill also mandates that the Hawaii Department of Human Services amend the Medicaid state plan to include these coverage requirements.